ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor

Dong Li(King University), Håkon Håkonarson(Children's Hospital of Philadelphia), Courtney N. Kaminski(Children's Hospital of Philadelphia), Jonathan A. Perkins(Seattle Children's Hospital), Yichuan Liu(Children's Hospital of Philadelphia), Michael March(Children's Hospital of Philadelphia), Leticia S. Matsuoka(Children's Hospital of Philadelphia), Matthew Swift(National Institute of Child Health), Patricia J. Hicks(University of Pennsylvania), Brant M. Weinstein(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Hyun Min Jung(University of Florida), Nora Robinson(Children's Hospital of Philadelphia), Janet T. Strausbaugh(University of Pennsylvania), Michael A. Levine(Children's Hospital of Philadelphia), Christoph Seiler(Children's Hospital of Philadelphia), Yoav Dori(Institute of Cardiology), Jean B. Belasco(California University of Pennsylvania), Rosetta Chiavacci(Children's Hospital of Philadelphia), Lifeng Tian(Children's Hospital of Philadelphia), Erin Pinto(Children's Hospital of Philadelphia), Patrick Sleiman(Children's Hospital of Philadelphia), Álvaro Gutiérrez-Uzquiza(Children's Hospital of Philadelphia), Elizabeth Bhoj(Children's Hospital of Philadelphia), Tiancheng Wang(Children's Hospital of Philadelphia), Tara Wenger(Seattle Children's Hospital), Charlly Kao(Children's Hospital of Philadelphia), Mark R. Battig(Children's Hospital of Philadelphia)

Nature Medicine

July 1, 2019

Cited by 221

|Developmental Biology|2002|2.2k

|Science|2018|2k

|Nature|2013|958

|Development|2001|920

|Developmental Biology|2001|916

Related Papers